Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

193.83 +5.42 (+2.88%)
Official Closing Price Updated: 7:00 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
S&P 500 Hits Fresh Records At 6,100: Strong Earnings, Trump's AI Wager Fuel Bull Run
Market surges on AI Stargate initiative & strong earnings. S&P 500 hits record high of 6,100 points, led by tech giants & semiconductor stocks. 
Via Benzinga
Topics Artificial Intelligence Government Stocks
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals. 
Via Benzinga
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
JNJ earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Johnson & Johnson Q4 Earnings And Revenues Top Estimates
Johnson & Johnson came out with quarterly earnings of $2.04 per share. 
Via Talk Markets
Topics Stocks / Equities
Chipmakers Rally On AI Stargate Bet, Netflix Soars, Bitcoin Falters As Trump Keeps Quiet On Crypto: What's Driving Markets Wednesday?
Tech stocks enjoyed a surge Wednesday, driven by a sharp rise in semiconductor shares after President Donald Trump, OpenAI's Sam Altman, Oracle Corp. 
Via Benzinga
Topics Artificial Intelligence Government
J&J Stock Dips As 2025 Sales Guidance Misses Estimate, But Retail Mood Resilient
During the earnings call, J&J highlighted several growth drivers, including its positioning for 5%-7% annual growth through 2030 and plans to increase its dividend annually. 
Via Stocktwits
Topics Earnings
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations. 
Via The Motley Fool
Topics Intellectual Property
Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook
Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts. 
Via Benzinga
Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light
The Dow Jones stock fell slightly early Wednesday. 
Via Investor's Business Daily
Topics Stocks
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
From Johnson & Johnson
Via Business Wire
US Stocks Likely To Open Higher As President Trump Announces $500 Billion AI Project: Oracle, Netflix, Nvidia Among Top Stocks To Watch
U.S. stocks could open on a positive note on Wednesday, continuing to rally after Donald Trump's inauguration as the 47th President of the U.S. on Monday. 
Via Benzinga
Topics Artificial Intelligence Government
Earnings Scheduled For January 22, 2025
 
Via Benzinga
Dow Jumps Over 500 Points As Trump Takes Office: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone
The CNN Business Fear & Greed Index measures market sentiment, with higher fear putting pressure on stocks. 
Via Benzinga
Topics Government Stocks
Netflix, Procter & Gamble And 3 Stocks To Watch Heading Into Wednesday
 
Via Benzinga
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
 
Via Benzinga
Big Trading Day Ends With Q4 Earnings Beats: NFLX, UAL, COF
Markets had a strong session on the first full day of President Trump’s second administration. Indexes have rocketed up from 2025 lows hit a week to a week and a half ago. 
Via Talk Markets
Topics Government Stocks / Equities
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price target - 13% upside 
Via Benzinga
Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?
Johnson & Johnson is one of several Dow Jones Industrial Average stocks reporting financial results this week. A look at the key items and numbers to watch. 
Via Benzinga
Topics Stocks
FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression
FDA approves Johnson & Johnson's Spravato nasal spray as a monotherapy for major depressive disorder, showing superior efficacy in clinical trials. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)
From Brodsky & Smith LLC
Via GlobeNewswire
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Via The Motley Fool
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Via The Motley Fool
Topics Stocks
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Via The Motley Fool
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals. 
Via Benzinga
MarketBeat Week in Review – 01/13 - 01/17
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally 
Via MarketBeat
Topics Economy Energy
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
Via The Motley Fool
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade
This magnificent company has been paying a continuous dividend to its shareholders since 1816. 
Via The Motley Fool
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.